SHL.DE Siemens Healthineers (XETRA) pre-market 31 Jan 2026: Q4 due Feb 5, margins in focus
We start pre-market with SHL.DE stock at €42.17, ahead of Siemens Healthineers’ Q4 results due on 5 Feb 2026. Investors will watch revenue, margins and Varian integration metrics. The shares trade on XETRA in Germany with a PE of 22.08 and EPS €1.91. Liquidity shows 1,015,366 shares traded today, signaling active positioning into the print.
Earnings timing and what to watch
Siemens Healthineers (SHL.DE) reports results on 5 Feb 2026. Key items: organic revenue growth, Imaging and Varian margins, Diagnostics service backlog, and guidance for FY. Management commentary on Varian synergies will move the stock. Expect analysts to parse EBIT margin and free cash flow versus targets.
Recent price action and valuation snapshot
SHL.DE stock trades at €42.17, near its 52-week low of €40.97 and well below the year high of €58.48. The stock’s PE is 22.08 with a dividend per share of €1.00 and yield near 2.25%. Fifty-day average is €44.19 and 200-day average is €46.22, indicating short-term underperformance versus longer-term trend.
Financials, margins and growth drivers
Revenue per share is €20.93 and net income per share is €1.92. Operating profit margin sits near 14.70% and R&D equals 8.38% of sales. Free cash flow per share is €2.03, with a payout ratio of 0.50. Long-term growth rests on Diagnostics volume recovery and Varian cancer-treatment expansion.
Technicals, liquidity and market context
Technicals show RSI 69.29 and MACD histogram positive, flagging near-term strength but overbought signals. Volume of 1,015,366 versus average 936,843 shows slightly elevated trade. In the Healthcare sector, peers show muted YTD interest; SHL.DE’s net debt to EBITDA of 2.81 is a leverage watch ahead of the release.
Meyka AI grade and model forecast
Meyka AI rates SHL.DE with a score out of 100. Meyka AI assigns SHL.DE a score 69.34 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €44.30 and yearly €47.33. At the current price €42.17, the yearly forecast implies an upside of 12.24%. Forecasts are model-based projections and not guarantees.
Earnings risks and upside scenarios
Downside risks include slower-than-expected Diagnostics recovery, Varian integration costs and FX pressure. Upside drivers are margin expansion in Imaging, accelerated Varian sales and improving service contracts. Realistic price targets: conservative €40.00, base €47.33, bull €55.00. Position size should reflect event-driven volatility.
Final Thoughts
Ahead of the 5 Feb 2026 Q4 release, SHL.DE stock trades at €42.17 with PE 22.08 and near-term volume above average. The print will hinge on margins, Varian momentum and free cash flow conversion. Meyka AI’s model projects €47.33 for the year, implying a 12.24% upside versus today. Investors should weigh the €1.00 dividend ex-date on 6 Feb 2026 source and sector dynamics versus healthcare peers. Use tight risk control around the announcement and monitor management commentary closely. Forecasts are model-based projections and not guarantees. For live updates see Meyka’s SHL.DE page and the Investing summary source or our internal coverage at Meyka SHL.DE.
FAQs
When does Siemens Healthineers report earnings?
Siemens Healthineers (SHL.DE) will report Q4 results on 5 Feb 2026. Expect commentary on margins, Varian integration and cash flow. The ex-dividend date for the €1.00 payment is 6 Feb 2026 source.
What is the current price and valuation for SHL.DE stock?
SHL.DE stock trades at €42.17 with EPS €1.91 and PE 22.08. The 50-day average is €44.19 and the 200-day average is €46.22, showing relative underperformance versus longer-term trend.
What does Meyka AI forecast for SHL.DE stock?
Meyka AI’s forecast model projects a yearly price of €47.33 for SHL.DE stock, implying roughly 12.24% upside from €42.17. Forecasts are model-based projections and not guarantees.
What are the main risks around the earnings release?
Key risks for SHL.DE stock include weaker Diagnostics demand, higher Varian integration costs, FX headwinds and softer service revenue. These factors could pressure margins and free cash flow.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
